Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GUTS Stock Forecast 2026-2027
$0.47
Current Price
$73.79M
Market Cap
Buy 5
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to GUTS Price Targets
+1,602.9%
To High Target of $8.00
+1,219.7%
To Median Target of $6.20
+325.7%
To Low Target of $2.00
GUTS Price Momentum
+2.2%
1 Week Change
-4.1%
1 Month Change
-50.5%
1 Year Change
-78.6%
Year-to-Date Change
-84.5%
From 52W High of $3.03
+24.6%
From 52W Low of $0.38
📊 TOP ANALYST CALLS
Did GUTS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Fractyl Health is one of their latest high-conviction picks.
Latest GUTS Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, GUTS has a bullish consensus with a median price target of $6.20 (ranging from $2.00 to $8.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $0.47, the median forecast implies a 1,219.7% upside. This outlook is supported by 5 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Whitney Ijem at Canaccord Genuity, projecting a 1,602.9% upside. Conversely, the most conservative target is provided by Michael Ulz at Morgan Stanley, suggesting a 325.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GUTS Analyst Ratings
5
Buy
1
Hold
0
Sell
GUTS Price Target Range
Low
$2.00
Average
$6.20
High
$8.00
Current: $0.47
Latest GUTS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GUTS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 26, 2026 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $8.00 |
| Jan 30, 2026 | Morgan Stanley | Michael Ulz | Equal-Weight | Downgrade | $2.00 |
| Dec 2, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $8.00 |
| Nov 21, 2025 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $8.00 |
| Sep 26, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $8.00 |
| Sep 15, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Initiates | $9.00 |
| Aug 28, 2025 | Ladenburg Thalmann | Jeff Cohen | Buy | Initiates | $3.60 |
| Aug 14, 2025 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $6.00 |
| Apr 15, 2025 | Canaccord Genuity | Buy | Initiates | $12.00 | |
| Feb 3, 2025 | Morgan Stanley | Michael Ulz | Overweight | Maintains | $10.00 |
| Feb 28, 2024 | Evercore ISI Group | Umer Raffat | Outperform | Initiates | $N/A |
| Feb 27, 2024 | Morgan Stanley | Michael Ulz | Overweight | Initiates | $18.00 |
Fractyl Health Inc. (GUTS) Competitors
The following stocks are similar to Fractyl Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
GUTS
Fractyl Health
mkt cap
72.33M
Fractyl Health Inc. (GUTS) Financial Data
Fractyl Health Inc. has a market capitalization of $73.79M with a P/E ratio of -0.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -744.2%.
Valuation Metrics
Market Cap
$73.79M
Enterprise Value
$52.43M
P/E Ratio
-0.5x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
-100.0%
Financial Health
Cash/Price Ratio
+109.4%
Current Ratio
4.8x
Debt/Equity
651.8x
ROE
-744.2%
ROA
-52.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Fractyl Health Inc. (GUTS) Business Model
About Fractyl Health Inc.
What They Do
Develops advanced treatments for metabolic diseases.
Business Model
Fractyl Health Inc. focuses on innovative procedural therapies that aim to modify the gastrointestinal tract to treat chronic metabolic and inflammatory diseases, particularly type 2 diabetes. The company generates revenue through its research and clinical trials, leading to potential partnerships and marketable therapies.
Additional Information
By addressing the root causes of metabolic disorders rather than just managing symptoms, Fractyl Health positions itself as a leader in the healthcare sector. Its commitment to research and development highlights its potential for significant impact and profitability in a market facing increasing demand for effective treatments.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
100
CEO
Dr. Harith Rajagopalan M.D., Ph.D.
Country
United States
IPO Year
N/A
Website
fractyl.comFractyl Health Inc. (GUTS) Latest News & Analysis
Latest News
Quick Summary
Fractyl Health, Inc. (GUTS) held its Q4 2025 earnings call, providing insights into financial performance and strategic direction. Specific details on earnings results were not included.
Why It Matters
The Q4 2025 earnings call for Fractyl Health, Inc. provides insights into financial performance, growth potential, and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Fractyl Health, Inc. (Nasdaq: GUTS) will report its Q4 and full-year 2025 financial results and business updates on March 24, 2026, at 4:30 p.m. ET.
Why It Matters
Fractyl Health's upcoming financial results announcement could indicate its growth trajectory and impact stock performance, especially in the healthcare sector focused on obesity and diabetes.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Fractyl Health, Inc. (GUTS) has received a Zacks Rank #2 (Buy) upgrade, indicating improved earnings prospects and potential for stock price appreciation.
Why It Matters
Fractyl Health's Zacks Rank upgrade signals improved earnings outlook, likely boosting investor confidence and potentially increasing the stock price in the short term.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Fractyl Health, Inc. completed participant randomization in its REMAIN-1 study evaluating Revita® for weight maintenance. Topline data expected in early Q4 2026; cash runway extends into early 2027.
Why It Matters
Upcoming pivotal data and FDA application timelines are crucial for Fractyl Health's market prospects. Cash runway extending into early 2027 provides financial stability during this critical phase.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Fractyl Health, Inc. (GUTS) Loses 77.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
1 month ago
Quick Summary
Fractyl Health, Inc. (GUTS) is in oversold territory, suggesting potential for a trend reversal, supported by Wall Street analysts revising earnings estimates higher.
Why It Matters
Fractyl Health, Inc. (GUTS) may be poised for a rebound as it shows oversold conditions and analysts are raising earnings estimates, signaling potential growth and investment opportunities.
Source: Zacks Investment Research
Market Sentiment:
Negative
Fractyl Health: Unreasonably Low Market Expectations Create A Trading Opportunity Towards 2026 Catalysts
2 months ago
Quick Summary
Fractyl Health presents a buy opportunity after a dip due to mixed pilot data for its Revita device. A pivotal Phase 3 obesity trial is well-funded, with results expected in 2H 2026.
Why It Matters
Fractyl Health presents a potential buying opportunity as positive long-term trial data offsets short-term pilot concerns, indicating potential growth in the obesity treatment market.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About GUTS Stock
What is Fractyl Health Inc.'s (GUTS) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Fractyl Health Inc. (GUTS) has a median price target of $6.20. The highest price target is $8.00 and the lowest is $2.00.
Is GUTS stock a good investment in 2026?
According to current analyst ratings, GUTS has 5 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.47. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GUTS stock?
Wall Street analysts predict GUTS stock could reach $6.20 in the next 12 months. This represents a 1,219.7% increase from the current price of $0.47. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Fractyl Health Inc.'s business model?
Fractyl Health Inc. focuses on innovative procedural therapies that aim to modify the gastrointestinal tract to treat chronic metabolic and inflammatory diseases, particularly type 2 diabetes. The company generates revenue through its research and clinical trials, leading to potential partnerships and marketable therapies.
What is the highest forecasted price for GUTS Fractyl Health Inc.?
The highest price target for GUTS is $8.00 from Whitney Ijem at Canaccord Genuity, which represents a 1,602.9% increase from the current price of $0.47.
What is the lowest forecasted price for GUTS Fractyl Health Inc.?
The lowest price target for GUTS is $2.00 from Michael Ulz at Morgan Stanley, which represents a 325.7% increase from the current price of $0.47.
What is the overall GUTS consensus from analysts for Fractyl Health Inc.?
The overall analyst consensus for GUTS is bullish. Out of 6 Wall Street analysts, 5 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $6.20.
How accurate are GUTS stock price projections?
Stock price projections, including those for Fractyl Health Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 10, 2026 2:59 AM UTC